16 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy https://www.fool.com/investing/2019/05/28/this-just-in-goldman-sachs-picks-4-big-pharma-stoc.aspx?source=iedfolrf0000001 May 28, 2019 - And the analyst really likes one in particular.
Why Cancer-Fighting Stocks & ETFs Are Soaring http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108 Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Merck's Keytruda Improves 5-Year Survival in Lung Cancer http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-ZC-FT-423872 Jun 03, 2019 - Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
Incyte Begins Phase III Study for Treatment of Duct Cancer http://www.zacks.com/stock/news/425849/incyte-begins-phase-iii-study-for-treatment-of-duct-cancer?cid=CS-ZC-FT-425849 Jun 06, 2019 - Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache http://www.zacks.com/stock/news/426292/pharma-stock-roundup-asco-update-fda-nod-for-llys-emgality-for-cluster-headache?cid=CS-ZC-FT-426292 Jun 07, 2019 - Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet http://www.zacks.com/stock/news/427034/lilly-lly-presents-data-from-diabetes-studies-at-ada-meet?cid=CS-ZC-FT-427034 Jun 10, 2019 - Lilly (LLY) presents additional data from studies on investigational diabetes products ultra-rapid-acting lispro and tirzepatide and outcomes study (REWIND) on Trulicity at ADA.
Top Analyst Reports for Oracle, Eli Lilly & Mondelez http://www.zacks.com/research-daily/427196/top-analyst-reports-for-oracle-eli-lilly-mondelez?cid=CS-ZC-FT-427196 Jun 10, 2019 - Top Analyst Reports for Oracle, Eli Lilly & Mondelez
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M http://www.zacks.com/stock/news/427724/merck-mrk-to-buy-private-biotech-tilos-for-up-to-%24773m?cid=CS-ZC-FT-427724 Jun 11, 2019 - Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod http://www.zacks.com/stock/news/429560/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod?cid=CS-ZC-FT-429560 Jun 14, 2019 - Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi http://www.zacks.com/stock/news/420060/incyte-incy-receives-fda-nod-for-label-expansion-of-jakafi?cid=CS-ZC-FT-420060 May 27, 2019 - Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.

Pages: 12

Page 1